Vanguard Group Inc. Trims Stock Position in Medpace Holdings, Inc. $MEDP

Vanguard Group Inc. lessened its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 2,261,848 shares of the company’s stock after selling 21,124 shares during the quarter. Vanguard Group Inc. owned approximately 0.08% of Medpace worth $1,270,367,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. NewEdge Advisors LLC increased its holdings in shares of Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after acquiring an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after acquiring an additional 3,010 shares during the period. Geneos Wealth Management Inc. increased its holdings in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of Medpace in the 2nd quarter valued at $296,000. Finally, M&T Bank Corp increased its holdings in shares of Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after acquiring an additional 31 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of MEDP opened at $418.66 on Friday. The stock has a market capitalization of $11.96 billion, a P/E ratio of 26.31, a P/E/G ratio of 2.10 and a beta of 1.39. The company’s fifty day moving average is $468.91 and its two-hundred day moving average is $532.81. Medpace Holdings, Inc. has a 1 year low of $284.10 and a 1 year high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. Medpace’s revenue was up 26.5% compared to the same quarter last year. During the same period in the previous year, the company posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Insider Transactions at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 20.50% of the company’s stock.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of recent research reports. Leerink Partners cut their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Truist Financial cut their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, Mizuho set a $582.00 target price on shares of Medpace in a report on Wednesday, February 11th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.